PHOENIX, Ariz. — Jan. 13, 2011 — Genomic research could help doctors better target a drug widely used to treat colorectal cancer patients, according to a study by Genomic Health Inc. (Nasdaq: GHDX) and the Translational Genomics Research Insti…
HOUSTON, Jan. 10, 2011 — Research with significant implications in the treatment and intervention of cancer and obesity has been published recently in two prestigious journals by University of Houston (UH) biochemist Dr. Jan-Åke Gustafsson….
CHAMPAIGN, Ill. — University of Illinois researchers are using a new kind of microsensor to answer one of the weightiest questions in biology — the relationship between cell mass and growth rate.
The team, led by electrical and computer engin…
Building on earlier studies that have shown that common painkillers known as NSAIDs (non-steroidal anti-inflammatory drugs) can reduce the risk of colon cancer in healthy people, researchers at Dana-Farber Cancer Institute have identified a mechanism by which NSAIDs inhibit the development of colon cancer. Compared with normal cells, colorectal cancer cells have abnormally high levels of an immune system protein, IL-6. David Frank, MD, PhD, and his Dana-Farber colleagues have discovered that IL-6 triggers malignant growth by activating a protein called STAT1, which transmits signals that prevent the normal scheduled death of cells in the colon.